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Abstract:
Background:
Type 2 diabetes mellitus (T2DM) is a risk factor for the development of non-alcoholic fatty liver disease, which can lead to liver
fibrosis and ultimately to cirrhosis. Transient elastography (TE), by using the FibroScan, and is a non-invasive ultrasonography
method to measure liver elasticity. TE has been related with the degree of liver fibrosis.
Objective:
To investigate the applicability of TE in daily clinical practice among T2DM patients.
Method:
In a non-academic teaching hospital, T2DM patients without a history of liver disease the degree of liver stiffness was measured
using TE. Successful  measurements  were defined as  10 validated measurements  per  patient  and an interquartile  range (IQR) to
median ratio of ≤30%.
Results:
In 90 of 126 patients (71%) valid measurements were be obtained. Among the patients with invalid measurements, 33 had < 10 valid
measurements and 3 had a IQR to median ratio of <30%. The percentage of invalid measurements was 12% in patients with a BMI
<30 kg/m2 and 39% in patients with a BMI ≥30 kg/m2. Among the 90 patients with valid liver stiffness measurements, the median
liver stiffness was 6.7 [4.6-8.5] kPa with a IQR of measurements of 1.1 [0.6-1.8] kPa and IQR to median ratio of 17 (13-23)%.
Conclusion:
The success rate of TE measurements using the FibroScan in patients with T2DM was 71%, with a lower success rate in patients with
a BMI ≥ 30 kg/m2. This diagnostic modality needs further investigation being introduced as a marker of fibrosis in daily diabetes
practice.
Keywords: FibroScan, Fibrosis, NAFLD, Transient elastography, Type 2 diabetes mellitus.
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INTRODUCTION
In the Western society, 20-30% of the people are considered to have Non-Alcoholic Fatty Liver Disease (NAFLD).
The  spectrum of  NAFLD ranges  from mild  hepatic  steatosis  to  Non-Alcoholic  SteatoHepatitis  (NASH)  [1].  If  left
untreated, NASH can progress to fibrosis, cirrhosis and eventually to the development of hepatocellular carcinoma [2].
Central obesity, dyslipidaemia and hypertension are risk factors for the development of NAFLD [3]. Persons with type
2 diabetes mellitus (T2DM) have an increased risk of developing NAFLD and also for progressing to cirrhosis and
hepatocellular carcinoma [4 - 10].
At present, a liver biopsy is the gold standard to diagnose and determine the severity of NAFLD [11]. Because a
liver biopsy is an invasive and laborious procedure, with possibly even (severe) complications, there is a search for non-
invasive methods for estimating the degree of fibrosis [12]. One of these new procedures is measurement of the degree
of liver fibrosis through transient elastography (TE) by FibroScan®, a non-invasive ultrasound examination measuring
liver elasticity. At present, the Fibroscan is already used in the management of hepatitis B and C.
Given the possible consequences of liver fibrosis there is growing interest in non-invasive methods for estimating
the risk of liver related complications such as TE. Therefore we aimed to investigate the applicability of TE in daily
clinical use in a secondary setting.
MATERIALS AND METHODS
Study Design and Population
The present study was a pilot study, conducted among patients with T2DM treated at the diabetes outpatient clinic
of the Isala (Zwolle, The Netherlands), a large non-academic teaching hospital. Consecutive patients were recruited
from the diabetes outpatient clinic, from June 2013 to August 2013. All patients aged 18 years or older with T2DM and
willing to participate were included. Participants with diabetes secondary to chronic pancreatitis, haemochromatosis,
genetically induced liver disease, known substance abuse or chronic viral hepatitis were excluded. The study protocol
(study registration number 13.0433 B 10111832) was approved by the local medical ethics committee and the study was
performed in accordance with the Declaration of Helsinki.
Measurements and Study Procedures
Liver stiffness measurements were performed using TE (FibroScan® 402, EchoSens, Paris, France) by one trained
investigator (SH), according to a standardized examination procedure which has been described in detail previously
[13]. A successful examination was defined as 10 validated measurements and an interquartile range (IQR) to median
ratio of ≤30% [14].  The standard medium (M)-probe was used for all  patients,  with a frequency of 3.5 MHz and a
measurement depth of 25 to 65 mm.
At the first visit, clinical and biological parameters were recorded according to standardized protocol; Body Mass
Index (BMI in kg/m2), waist circumference (cm), blood pressure (mmHg), alcohol use (number of units per day) and
tobacco use (pack years), medication use, duration of diabetes, microvascular (nephropathy, retinopathy or neuropathy)
and  macrovascular  complications.  Patients  were  considered  to  have  macrovascular  complications  when  they  had  a
previous history of myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), coronary artery
bypass grafting (CABG), stroke (CVA) or peripheral arterial disease. Peripheral arterial disease was defined as an ankle
brachial index <0.9. Most recent laboratory values were collected: platelet count, prothrombin time (PT), creatinine,
alkaline  phosphatase  (ALP),  ү-glutamyl-transpeptidase  (yGT),  aspartate  aminotransferase  (AST),  alanine
aminotransferase (ALT), glycated haemoglobin (HbA1c) and urinary albumin/creatinine ratio. Laboratory data were
determined using standard hospital procedures, performed at the department of clinical chemistry of the Isala Hospital.
HbA1c was measured using affinity chromatography high-performance liquid chromatography [15].
Primary and Secondary Outcomes
The primary outcome was defined as the percentage of valid measurements of liver elasticity. Secondary outcome
measures included the outcomes of the liver elastic measurements, clinical differences in patients with and without valid
measurements and differences according to BMI.
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Statistical Analysis
All data were expressed as number (%), mean ± standard deviation or median [interquartile range], as appropriate.
Normality  was  evaluated  using  Q-Q plots  and  histograms.  For  continuous  data,  comparisons  between groups  were
assessed using the Wilcoxon rank sum test. Categorical variables were compared by Chi2-test. Statistical analyses were
performed using the statistical commercial software IBM SPSS Statistics Version 21.0. A two-sided p-value of <0.05
was considered to be statistically significant.
RESULTS
Patients
From June 3 through August 27, 2013, a total of 191 individuals with T2DM were assed for eligibility and received
information about the study. During the subsequent outpatient clinic visit, 56 patients declined to participate and 9 did
not  meet  the  inclusion  criteria  due  to  no  diagnosis  of  T2DM  (n=5)  or  a  diagnosis  of  haemochromatosis  (n=4).
Subsequently,  TE  measurements  were  conducted  in  126  patients.  As  presented  in  Table  1,  the  mean  age  of  these
patients was 65.2 ± 12.8 years, 51% was male and the median body mass index (BMI) was 31.4 [28.3-34.6] kg/m2.







Male sex 64 (50.8) 15 (41.7) 49 (54.4)
Age (years) 65.2 ± 12.8 67.2 ± 11.7 64.4 ± 13.2
BMI (kg/m2) 31.4 [28.3-34.6] 33.1[30.7-36.4]* 30.3 [27.3-33.3]*
Systolic blood pressure (mmHg) 130.5 ± 15.3 134.9 ± 15.5 133.0 ± 15.3
Alcohol use (units of alcohol/day) 0.0 [0.0-1.0] 0.0 [0.0-0.3] 0.0 [0.0-1.0]
Tobacco use (pack/year) 6.4 [0-24.7] 5.5 [0-33.9] 6.9 [0-22.9]
Duration of diabetes (years) 15.2 ± 8.8 16.0 ± 6.8 14.9 ± 9.5
Medication diabetes (%) 124 (98.4) 36 (100) 88 (97.8)
 Oral (%) 84 (66.7) 24 (66.7) 60 (66.7)
 Metformin (%) 70 (55.6) 16 (44.4) 54 (60.0)
 Insulin (%) 104 (82.5) 33 (91.7) 71 (78.9)
Microvascular complications (%) 91 (72.2) 30 (83.3) 61 (67.8)
Macrovascular complications (%) 50 (39.7) 19 (52.8) 31 (34.4)
Myocardial infarction (%) 32 (25.4) 9 (25.0) 23 (25.6)
PTCA (%) 23 (18.3) 8 (22.2) 15 (16.7)
CABG (%) 20 (15.9) 4 (11.1) 16 (17.8)
Stroke (%) 12 (9.5) 6 (16.7) 6 (6.7)
Arterial disease (%) 11 (8.7) 3 (8.3) 8 (8.9)
Results are expressed as n(%), mean ± SE or median [IQR]. * p-value <0.05, comparison between groups. Abbreviations: BMI, Body Mass Index;
PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; IQR, interquartile range.
Primary Outcome
Amongst the 126 TE measurements performed, 36 persons (28.6%) had an invalid measurement, translating into a
success rate of 71.4%. Among the patients with an invalid measurement, 33 had < 10 valid measurements and 3 had a
IQR to median ratio of < 30%.
Secondary Outcomes
Among the 90 patients with valid liver stiffness measurements, the median liver stiffness was 6.7 [4.6-8.5] kPa with
a IQR of measurements of 1.1 [0.6-1.8] kPa and IQR to median ratio of 17 (13-23)%. Besides a higher BMI (33.1
[30.7-36.4] vs. 30.3 [27.3-33.3] kg/m2, p=0.001) there were no clinical differences between patients with and without
valid measurements (see Table 1).
In patients with a BMI ≥30 kg/m2 (n=77), significantly less valid liver stiffness measurements were obtained than in
patients with a lower BMI (61% vs. 88%, p=0.001). In multivariate analysis the median liver stiffness among patients
with a valid measurement was not associated with age, BMI, alcohol use and ASAT concentrations.
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DISCUSSION
TE, using the FibroScan,  is  an interesting and emerging non-invasive ultrasonography method to measure liver
elasticity  [13].  TE  has  been  related  with  the  degree  of  liver  fibrosis.  The  aim  of  our  study  was  to  investigate  the
applicability of TE in clinical practice among T2DM patients without a known history of liver disease. The success rate
of TE measurements was 71%, with a lower success rate among obese patients (BMI ≥30 kg/m2).
This success rate is somewhat lower than the success rate of 82% found in the only previous study by De Ledinghen
et  al.  investigating  diabetes  patients  treated  in  a  tertiary  care  setting  [16].  The  higher  average  BMI,  recently
demonstrated to negatively influence the success rate of TE, in the present study (31.8 ± 5.3 kg/m2 vs. 25.3 ± 4.5 kg/m2)
could explain this difference [17]. Moreover, the use of the M-probe in the present study may also account for the lower
success rate found in the present study. Since the M-probe reached depths of 25 to 65 mm, in quite a few subjects
subcutaneous fat accumulation hampered the sound waves even reaching the liver or preventing sufficiently reliable and
reproducible measurements. Although speculative, the use of a recently developed XL-probe, specifically designed for
patients with a high BMI, would possibly have led to more valid measurements [18, 19].
Among patients with valid liver stiffness measurements, the median liver stiffness was 6.7 [4.6-8.5] kPa. For post-
hoc hypothesis generation we used a cut-off point of 8.7 kPa, in accordance with Wong et al. who defined a best cut-off
value for METAVIR fibrosis score F3 (numerous septa present but no cirrhosis) or greater, i.e.  METAVIR fibrosis
score  F4  (cirrhosis  present),  of  8.7  kPa  in  TE measurements  as  abnormal  [20].  Using  this  cut-off  value,  22.2% of
patients with a valid measurement had a TE measurement >8.7 kPa. As compared to patients with a measurement <8.7
kPa,  these  patients  had  a  significantly  higher  BMI,  used  tobacco  more  frequently,  had  more  macrovascular
complications and had higher yGT concentrations (see Appendix 1). Furthermore, there appeared to be a relatively
strong positive correlation (r=0.84, N=39, p<0.001) between liver stiffness and the concentration of yGT (U/L) (see
Appendix 1). Nevertheless, it should be concluded that the clinical relevance of the present study is unclear at present
and requires further investigation.
CONCLUSION
In the present study the success rate of TE measurements using the FibroScan in patients with T2DM was 71%, with
a lower success rate in patients with a BMI ≥ 30 kg/m2.  Based on our data routinely performing TE as a screening
instrument should not be recommended. Although promising, this diagnostic modality needs further investigation being
introduced as a marker of fibrosis in daily diabetes practice.
APPENDIX
Appendix 1. Post-hoc analysis among persons with valid measurements, above and below 8.7kPa.
TE result ≤ 8.7 kPa
(N=70)
TE result > 8.7 kPa
(N=20)
Male sex 39 (55.7) 10 (50.0)
Age (years) 65.0 ± 12.8 62.4 ± 14.5
BMI (kg/m2) 29.6 [26.9-32.4] 32.2 [29.2-35.1] *
Systolic blood pressure (mmHg) 133.9 ± 16.3 129.6 ± 10.5
Alcohol use (units of alcohol/day) 0.86 0.81
Tobacco use (pack/year) 4.3 (0-20.0) 19.3 (0.8-39.0) *
Duration of diabetes (years) 14.9 ± 9.6 14.7 ± 9.7
Medication diabetes (%) 69 (98.6) 19 (95.0)
Oral hypoglycemic agents (%) 47 (67.1) 13 (65.0)
 Metformin (%) 42 (60.0) 12 (60.0)
 Insulin (%) 57 (81.4) 14 (70.0)
Microvascular complications (%) 47 (67.1) 14 (70.0)
Macrovascular complications (%) 21 (30.0) 10 (50.0)
Myocardial infarction (%) 14 (20.0) 9 (45.0) *
PTCA (%) 13 (18.6) 2 (10.0)
CABG (%) 8 (11.4) 8 (40.0) *
Stroke (%) 5 (7.1) 1 (5.0)
Peripheral arterial disease (%) 4 (5.7) 4 (20.0) *
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TE result ≤ 8.7 kPa
(N=70)
TE result > 8.7 kPa
(N=20)
Liver stiffness (kPa) 5.8 [4.3-7.4] 12.2 [10.2-20.4]
IQR (kPa) 0.9 [0.5-1.3] 2.9 [2.2-3.8]
IQR/median (%) 16 [11-23] 22 [16-28]
Results are expressed as n(%), mean ± SE or median [IQR]. * p-value <0.05, comparison between groups. Abbreviations: BMI, Body Mass Index;
PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; IQR, interquartile range.
This study is one of the first to study the effect of the Fibroscan, nevertheless limitations of the present study should
be mentioned. First and foremost, we did not compare the FibroScan to the gold standard (liver biopsy) to confirm a
valid measurement. Furthermore, the generalizability of the findings of the present study are limited by the relative
small study size of Caucasian patients and the lack of a pre-study power calculation. On the other hand, study provides
information  regarding  the  clinical  applicability  of  TE  using  the  FibroScan  in  T2DM  patients  during  real-life
circumstances.
Nevertheless,  at  the  moment  the  use  of  routinely  performing  TE  as  a  screening  instrument  should  not  be
recommended. Whether TE could be used for excluding advanced fibrosis instead of liver biopsy in T2DM should
preferably be investigated in patients with an indication for liver biopsy, combining TE measurements with the liver
biopsy information.
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